PDGFRalpha is an Oncofetal Target in Human Hepatocellular Cancer

Peggy Stock,Dulabh Monga,Amanda Micsenyi,Xinping Tan,Gang Zeng,Nick Loizos,Satdarshan P. S. Monga
DOI: https://doi.org/10.1096/fasebj.21.6.a1138-b
2007-01-01
The FASEB Journal
Abstract:Hepatocellular cancer (HCC) is a disease of poor prognosis. Owing to the similarities between the processes of development and carcinogenesis, we utilized early developing livers to recognize differentially expressed genes and analyzed their expression in HCC. Livers from various mouse embryos (E11‐E18) were utilized for gene and protein analysis. Patient HCC tissues (n=22), normal adjacent preneoplastic tissue and normal livers were examined for PDGFRα by Western and Real‐Time PCR. The upstream effectors such as PDGF‐A and PDGF‐C were also examined. Finally, therapeutic effect of anti‐PDGFRα antibody (MAb3G3; ImClone) was investigated on human hepatoma cells.
What problem does this paper attempt to address?